Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-B-cell maturation antigen chimeric antigen receptor T-cell-Shenzhen Second People's Hospital-multiple myeloma
- Development stage
- Unknown
- Lead developer
- Shenzhen Second People’s Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational, hospital-developed **autologous anti-BCMA CAR-T-cell therapy** evaluated by Shenzhen Second People's Hospital for relapsed or refractory BCMA-positive multiple myeloma. Patient T cells are engineered ex vivo to express a chimeric antigen receptor directed against B-cell maturation antigen, enabling CAR-T-cell activation and cytotoxic elimination of BCMA-expressing malignant plasma cells. The material is not assigned a unique product code, INN, or brand name and represents a site-specific BCMA CAR-T program studied in the Phase I trial NCT03767725.
- Other names
- anti-BCMA CAR-Tanti-B-cell maturation antigen chimeric antigen receptor T-cell
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-B-cell maturation antigen chimeric antigen receptor T-cell-Shenzhen Second People's Hospital-multiple myeloma.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-B-cell maturation antigen chimeric antigen receptor T-cell-Shenzhen Second People's Hospital-multiple myeloma.